Schedule 13G ownership disclosure
Avalo Therapeutics, Inc.
Common Stock, par value $0.001 per share · CUSIP: 05338F306
Event date: 2025-09-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Affinity Healthcare Fund, LP
Shares: 1,006,217.00 · Class: 7.65%
- Affinity Asset Advisors, LLC
Shares: 1,006,217.00 · Class: 7.65%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001999371-25-017697
- Form type
- SCHEDULE 13G/A
- Filer
- Affinity Asset Advisors, LLC
- CIK
- CIK 1773195
- Filed
- Nov 13, 2025
- Reporting period
- Sep 30, 2025
- Description
- Schedule 13G beneficial ownership